1.Cross-Protective Immune Responses Elicited by Live Attenuated Influenza Vaccines.
Yonsei Medical Journal 2013;54(2):271-282
The desired effect of vaccination is to elicit protective immune responses against infection with pathogenic agents. An inactivated influenza vaccine is able to induce the neutralizing antibodies directed primarily against two surface antigens, hemagglutinin and neuraminidase. These two antigens undergo frequent antigenic drift and hence necessitate the annual update of a new vaccine strain. Besides the antigenic drift, the unpredictable emergence of the pandemic influenza strain, as seen in the 2009 pandemic H1N1, underscores the development of a new influenza vaccine that elicits broadly protective immunity against the diverse influenza strains. Cold-adapted live attenuated influenza vaccines (CAIVs) are advocated as a more appropriate strategy for cross-protection than inactivated vaccines and extensive studies have been conducted to address the issues in animal models. Here, we briefly describe experimental and clinical evidence for cross-protection by the CAIVs against antigenically distant strains and discuss possible explanations for cross-protective immune responses afforded by CAIVs. Potential barriers to the achievement of a universal influenza vaccine are also discussed, which will provide useful guidelines for future research on designing an ideal influenza vaccine with broad protection without causing pathogenic effects such as autoimmunity or attrition of protective immunity against homologous infection.
Adaptive Immunity
;
Antigens, Viral/immunology
;
*Cross Protection
;
Genome, Viral
;
Humans
;
Immunity, Innate
;
Influenza Vaccines/*immunology/therapeutic use
;
Influenza, Human/*prevention & control
;
Orthomyxoviridae/genetics/immunology
;
Vaccines, Attenuated
3.Efficacy, Immunogenicity and Safety of a Human Rotavirus Vaccine RIX4414 in Singaporean Infants.
Kong Boo PHUA ; Fong Seng LIM ; Seng Hock QUAK ; Bee Wah LEE ; Yee Leong TEOH ; Pemmaraju V SURYAKIRAN ; Htay Htay HAN ; Hans L BOCK
Annals of the Academy of Medicine, Singapore 2016;45(2):44-50
INTRODUCTIONThis was the first study conducted to evaluate the efficacy of 2 oral doses of the human rotavirus vaccine, RIX4414 in Singaporean infants during the first 3 years of life.
MATERIALS AND METHODSHealthy infants, 11 to 17 weeks of age were enrolled in this randomised (1:1), double-blinded, placebo-controlled study to receive 2 oral doses of RIX4414 vaccine/placebo following a 0-, 1-month schedule. Vaccine efficacy against severe rotavirus (RV) gastroenteritis (Vesikari score ≥11) caused by wild-type RV strains from a period starting from 2 weeks post-Dose 2 until 2 and 3 years of age was calculated with 95% confidence interval (CI). Immunogenicity and safety of the vaccine were also assessed.
RESULTSOf 6542 infants enrolled, 6466 were included in the efficacy analysis and a subset of 100 infants was included in the immunogenicity analysis. Fewer severe RV gastroenteritis episodes were reported in the RIX4414 group when compared to placebo at both 2 and 3 year follow-up periods. Vaccine efficacy against severe RV gastroenteritis at the respective time points were 93.8% (95% CI, 59.9 to 99.9) and 95.2% (95% CI, 70.5 to 99.9). One to 2 months post-Dose 2 of RIX4414, 97.5% (95% CI, 86.8 to 99.9) of infants seroconverted for anti-RV IgA antibodies. The number of serious adverse events recorded from Dose 1 until 3 years of age was similar in both groups.
CONCLUSIONTwo oral doses of RIX4414 vaccine was immunogenic and provided high level of protection against severe RV gastroenteritis in Singaporean children, during the first 3 years of life when the disease burden is highest.
Antibodies, Viral ; immunology ; Double-Blind Method ; Female ; Gastroenteritis ; prevention & control ; virology ; Humans ; Immunogenicity, Vaccine ; Immunoglobulin A ; immunology ; Infant ; Male ; Rotavirus ; immunology ; Rotavirus Infections ; prevention & control ; Rotavirus Vaccines ; immunology ; therapeutic use ; Singapore ; Treatment Outcome ; Vaccines, Attenuated ; immunology ; therapeutic use
4.Protection of chickens from Newcastle disease with a recombinant baculovirus subunit vaccine expressing the fusion and hemagglutininneuraminidase proteins.
Youn Jeong LEE ; Haan Woo SUNG ; Jun Gu CHOI ; Eun Kyoung LEE ; Hachung YOON ; Jae Hong KIM ; Chang Seon SONG
Journal of Veterinary Science 2008;9(3):301-308
Recombinant baculoviruses containing the fusion (F) and hemagglutinin-neuraminidase (HN) glycoprotein gene of the viscerotropic velogenic (vv) Newcastle disease virus (NDV) isolate, Kr-005/00, and a lentogenic La Sota strain of the NDV were constructed in an attempt to develop an effective subunit vaccine to the recent epizootic vvNDV. The level of protection was determined by evaluating the clinical signs, mortality, and virus shedding from the oropharynx and cloaca of chickens after a challenge with vvNDV Kr-005/00. The recombinant ND F (rND F) and recombinant HN (rND HN) glycoproteins derived from the velogenic strain provided good protection against the clinical signs and mortality, showing a 0.00 PI value and 100% protection after a booster immunization. On the other hand, the combined rND F + HN glycoprotein derived from the velogenic strain induced complete protection (0.00 PI value and 100% protection) and significantly reduced the amount of virus shedding even after a single immunization. The rND F and rND HN glycoproteins derived from the velogenic strain had a slightly, but not significantly, greater protective effect than the lentogenic strain. These results suggest that the combined rND F + HN glycoprotein derived from vvNDV can be an ideal subunit marker vaccine candidate in chickens in a future ND eradication program.
Animals
;
Baculoviridae/genetics/*immunology
;
Chickens/*virology
;
DNA Primers
;
Gene Amplification
;
HN Protein/genetics/*therapeutic use
;
Korea
;
Marek Disease/immunology/prevention & control
;
Newcastle Disease/immunology/*prevention & control
;
Spodoptera/virology
;
Vaccines, Synthetic/genetics/therapeutic use
;
Viral Vaccines/genetics/therapeutic use
5.Preliminary study on nasal spray of interferon alpha-2b used for prevention of rubella and measles virus infections.
Jing ZHAO ; Feng-cai ZHU ; Yue-long SHU ; Rui ZHOU ; Li-qi LIU ; Li-lan ZHANG ; Zhi-yang SHI ; Zhen TANG ; Li-zhuo LIN ; Zhi-ai YU ; Li-ping ZHANG ; Bin ZHANG ; Yun-de HOU
Chinese Journal of Experimental and Clinical Virology 2005;19(3):220-222
OBJECTIVETo evaluate the efficacy of the interferon alpha-2b nasal spray in prevention of rubella and measles virus infections.
METHODSThe properly selected volunteer groups have been divided into interferon alpha-2b experimental and control group. The experimental group received interferon alpha-2b treatment by nasal spray for 2 days before the immunization, then both groups were challenged with rubella and measles attenuated live vaccine respectively through nasal spray. The sera from pre-immunization and 21 and 28 days after immunization were collected to test the IgG antibody titers. The influence on the viral antibody titer reflects the viral preventive effect by interferon alpha-2b.
RESULTSThe antibody titer difference of measles virus between experimental and control group was 1.26 (21 day) and 2.96 (28 day), there were statistically difference between them; the difference of rubella virus was 0.95 (21 day) and 0.37 (28 day), but there were no statistically differences found.
CONCLUSIONThe preliminary results showed that the interferon alpha-2b can be used as prevention method for measles and rubella viral infections.
Administration, Intranasal ; Adult ; Antibodies, Viral ; blood ; Antiviral Agents ; administration & dosage ; therapeutic use ; Female ; Humans ; Interferon-alpha ; administration & dosage ; therapeutic use ; Male ; Measles ; immunology ; prevention & control ; virology ; Measles Vaccine ; immunology ; therapeutic use ; Measles virus ; drug effects ; immunology ; Recombinant Proteins ; Rubella ; immunology ; prevention & control ; virology ; Rubella Vaccine ; immunology ; therapeutic use ; Rubella virus ; drug effects ; immunology ; Treatment Outcome ; Vaccination ; methods ; Vaccines, Attenuated ; immunology ; therapeutic use ; Young Adult
6.Safety and immunogenicity of seasonal inactivated influenza vaccine (split virion) and cross-reactive antibody responses to the H7N9 avian influenza virus.
Wanshen GUO ; Jin XU ; Junyu WU ; Sheng ZHAO ; Hongxia HE ; Wenjun SHI ; Dan YU ; Jing LI ; Hong GAO ; Jiangting CHEN
Chinese Journal of Epidemiology 2014;35(8):949-952
OBJECTIVETo evaluate the safety and immunogenicity of seasonal inactivated influenza vaccine (split virion) and to analyze its cross-reactive antibody responses to H7N9 avian influenza virus.
METHODSAn open-labeled clinical trial was carried out in infants aged 6-35 months, adults aged 18-60 years and the elderly aged >60 years. After vaccinations (one dose for adults and the elderly and two doses for infants), adverse events were observed. Serum samples were obtained before vaccination and 21 days after vaccination from adults and elderly subjects. Three types of antibody against seasonal influenza virus and antibody against H7N9 avian influenza virus were tested using microhemagglutination inhibition (HI) assay. Immunogenicity of the vaccine was evaluated based on the immunogenicity criteria for adults and the elderly, set by the Committee for Medicinal Products for Human Use (CHMP) for the European Medicines Agency.
RESULTSA total of 202 subjects (65 infants, 69 adults and 68 elderly) were enrolled and injected for at least one dose. The overall rate of adverse events was 12.4% (25/202) and most of them were under systemic reaction. No serious adverse event was reported. Pre- and post-vaccination serum samples were collected from 124 subjects (64 adults, 60 elderly). After 21 days of vaccination, the sero-conversion rate, sero-protection rate, and geometric mean titer (GMT) ratio (post-/pre-vaccination) of antibody against seasonal influenza virus were 78.1%-90.6%, 92.2%-100.0% and 7.9-41.0 among adults while 66.7%-83.3%, 86.7%-100.0% and 5.7-20.4 among the elderly, respectively. However, after vaccination, both sero-conversion rate and sero-protection rate of antibody against H7N9 avian influenza virus among adults and the elderly became zero, with GMT ratio between 1.2 and 1.4.
CONCLUSIONThis trial vaccine appeared to have good safety and immunogenicity but inducing no cross-reactive antibody response to H7N9 avian influenza virus.
Adult ; Aged ; Aged, 80 and over ; Antibodies, Viral ; blood ; Antibody Formation ; Child, Preschool ; Cross Reactions ; Hemagglutination Inhibition Tests ; Humans ; Infant ; Influenza A Virus, H7N9 Subtype ; Influenza Vaccines ; immunology ; therapeutic use ; Middle Aged ; Vaccines, Inactivated ; immunology ; therapeutic use ; Young Adult
7.A pilot study on the combined therapy of granulocyte-macrophage colony-stimulating factor and hepatitis B vaccine on chronic hepatitis B virus carrier children.
Jianshe WANG ; Qirong ZHU ; Ting ZHANG ; Hui YU
Chinese Medical Journal 2002;115(12):1824-1828
OBJECTIVETo observe the efficacy of treating intrauterine infected chronic hepatitis B virus (HBV) carrier children with a combination of granulocyte-macrophage colony-stimulating factor (GM-CSF) or hepatitis B immunoglobulin (HBIG) plus recombinant hepatitis B vaccine (rHBvac).
METHODSA total of 27 chronic HBV infected children, who were born to HBV carrier mothers and received hepatitis B immunoprophylaxis at birth, were randomized into 2 groups: one receiving a combined therapy of 50 micro g of GM-CSF plus 10 micro g of rHBvac injected intramuscularly at the same location (GM-CSF group, 14 children) or 200 IU HBIG and 10 micro g rHBvac in different muscles (HBIG group, 13 children) on a monthly four-dose schedule. HBV-DNA quantification and other HBV serological markers were tested before and after the four-dose therapy.
RESULTSTwelve children in each group completed the study. Of them, 3 children in the GM-CSF group and 4 in the HBIG group had elevated serum alanine transaminase (ALT) before the trial, and then 2 in each group became ALT normal after the treatment. Before the therapy, hepatitis B e antigen (HBeAg) positivity was found in nine children in the GM-CSF group and 10 in the HBIG group. One from each group had an HBeAg/anti-HBe seroconversion after the treatment. The quantity of HBV-DNA was significantly lower after the treatment (P = 0.023) in GM-CSF group, but was not significantly reduced in HBIG group. No subjects were found to be negative for hepatitis B surface antigen (HBsAg) after the treatment, and no serious adverse events occurred in either group.
CONCLUSIONCombined GM-CSF and rHBvac therapy inhibit HBV replication in carrier children who were not protected after treatment with immunoprophylaxis.
Carrier State ; therapy ; Child ; Child, Preschool ; Combined Modality Therapy ; DNA, Viral ; blood ; Granulocyte-Macrophage Colony-Stimulating Factor ; therapeutic use ; Hepatitis B Vaccines ; immunology ; Hepatitis B, Chronic ; therapy ; Humans ; Immunoglobulins ; therapeutic use ; Pilot Projects ; Vaccines, Synthetic ; immunology
8.Effects of DDA, CpG-ODN, and plasmid-encoded chicken IFN-gamma on protective immunity by a DNA vaccine against IBDV in chickens.
Ha Jung ROH ; Haan Woo SUNG ; Hyuk Moo KWON
Journal of Veterinary Science 2006;7(4):361-368
This study examined the adjuvant effects of dimethyl dioctadecyl ammonium bromide (DDA), CpG oligodeoxynucleotides (CpG-ODN), and chicken interferon-gamma (ChIFN-gamma) on a DNA vaccine (pcDNA-VP243) against the infectious bursal disease virus (IBDV). A plasmid encoding chicken IFN-atilde was constructed. Twice at 2-week intervals, twoweek-old chickens were injected intramuscularly and intraperitoneally with either a DNA vaccine alone or a DNA vaccine together with the respective adjuvants. On week 2 after the second immunization, the chickens were orally challenged with the highly virulent IBDV. The groups that received the DNA vaccines plus either DDA or CpG-ODN showed significantly lower survival rates than the group that received the DNA vaccine alone. However, the survival rates for the DNA vaccine alone and for the DNA vaccine plus ChIFN-gamma were similar. The chickens had no detectable antibodies to the IBDV before the challenge but all the surviving chickens in all groups except for the normal control group showed the induction of antibodies to the IBDV at day 10 after the challenge. As judged by the lymphocyte proliferation assays using the a WST-8 solution performed on the peripheral blood and splenic lymphocytes, the stimulation indices (SI) of the peripheral blood lymphocytes in all groups except for the normal control group were similar immediately before the challenge. At 10 days post-challenge, the SI for DNA vaccine plus either CpG-ODN or ChIFN-gamma was similar to that of the DNA vaccine control group. For splenic lymphocytes, the SI in the DNA vaccine plus CpG-ODN and DNA vaccine plus ChIFN-gamma groups were higher than for the DNA vaccine control. These results suggest that DDA actually compromises the protection against the IBDV by DNA vaccine, and CpG-ODN and IFN-gamma had no significant effect.
Adjuvants, Immunologic
;
Animals
;
Antibodies, Viral/blood
;
Birnaviridae Infections/*immunology/*prevention & control/virology
;
Bursa of Fabricius/immunology/virology
;
Cell Proliferation
;
Chickens
;
CpG Islands/immunology
;
Enzyme-Linked Immunosorbent Assay/veterinary
;
Immunization/methods/*veterinary
;
Infectious bursal disease virus/*immunology
;
Interferon-gamma/immunology/therapeutic use
;
Lymphocytes/cytology/immunology
;
Oligonucleotides/immunology
;
Poultry Diseases/immunology/*prevention & control/*virology
;
Specific Pathogen-Free Organisms
;
Vaccines, DNA/immunology/therapeutic use
;
Viral Vaccines/*immunology/therapeutic use
9.LMP2-DC Vaccine Elicits Specific EBV-LMP2 Response to Effectively Improve Immunotherapy in Patients with Nasopharyngeal Cancer.
Yi ZENG ; Yong Feng SI ; Gui Ping LAN ; Zhan WANG ; Ling ZHOU ; Min Zhong TANG ; O Brien SJ ; Jiao LAN ; Xiang Yang ZHOU ; Yong Li WANG ; Juan TANG ; Zhi Xiang ZHOU ; Hai Jun DU ; Hui LIN
Biomedical and Environmental Sciences 2020;33(11):849-856
Objective:
To evaluate the safety and effectiveness of a vaccine based on latent membrane protein 2 (LMP2) modified dendritic cells (DCs) that boosts specific responses of cytotoxic T lymphocytes (CTLs) to LMP2 before and after intradermal injection in patients with nasopharyngeal carcinoma (NPC).
Methods:
DCs were derived from peripheral blood monocytes of patients with NPC. We prepared LMP2-DCs infected by recombinant adenovirus vector expressing LMP2 (rAd-LMP2). NPC patients were immunized with 2 × 10
Results:
We demonstrated that DCs derived from monocytes displayed typical DC morphologies; the expression of LMP2 in the LMP2-DCs vaccine was confirmed by immunocytochemical assay. Twenty-nine patients with NPC were enrolled in this clinical trial. The LMP2-DCs vaccine was well tolerated in all of the patients. Boosted responses to LMP2 peptide sub-pools were observed in 18 of the 29 patients with NPC. The follow-up data of 29 immunized patients from April, 2010 to April 2015 indicated a five-year survival rate of 94.4% in responders and 45.5% in non-responders.
Conclusion
In this pilot study, we demonstrated that the LMP2-DCs vaccine is safe and effective in patients with NPC. Specific CTLs responses to LMP2 play a certain role in controlling and preventing the recurrence and metastasis of NPC, which warrants further clinical testing.
Adult
;
Aged
;
Cancer Vaccines/therapeutic use*
;
China
;
Dendritic Cells/immunology*
;
Female
;
Humans
;
Immunotherapy/methods*
;
Injections, Intradermal
;
Male
;
Middle Aged
;
Nasopharyngeal Carcinoma/therapy*
;
Nasopharyngeal Neoplasms/therapy*
;
T-Lymphocytes, Cytotoxic/immunology*
;
Viral Matrix Proteins/therapeutic use*
;
Young Adult
10.Advances on antigen-antibody immunogenic complex therapeutic vaccine for viral hepatitis B.
Xuan-yi WANG ; Xin YAO ; Li-min GUO ; Li-feng XU ; Xin-liang SHEN ; Dao-zhen XU ; Kai ZHAO ; Yu-mei WEN
Chinese Journal of Hepatology 2009;17(9):718-720
Animals
;
Antigen-Antibody Complex
;
therapeutic use
;
DNA, Viral
;
blood
;
Dendritic Cells
;
immunology
;
Ducks
;
Female
;
Hepatitis B Antibodies
;
blood
;
immunology
;
Hepatitis B Surface Antigens
;
immunology
;
Hepatitis B Vaccines
;
immunology
;
therapeutic use
;
Hepatitis B e Antigens
;
blood
;
immunology
;
Hepatitis B virus
;
immunology
;
Hepatitis B, Chronic
;
blood
;
immunology
;
therapy
;
Humans
;
Male
;
Mice
;
T-Lymphocytes